Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Cancer Med. 2023 Jan;12(2):1709-1720. doi: 10.1002/cam4.5012. Epub 2022 Jul 25.
Recently, serum exosomal circular RNAs (circRNAs) were applied to discriminate cancer patients from healthy individuals, indicating that exosomal circRNAs have the potential to be novel biomarkers for cancer diagnosis. This study aims to summarize the role of exosomal circRNAs in cancer diagnosis by a meta-analysis.
A comprehensive literature search was conducted up to July 2021 in PubMed, Web of Science, EMBASE, and Cochrane Database. To evaluate the diagnostic value, the sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were pooled. Threshold effect followed by subgroup analysis and meta-regression were performed to explore the source of heterogeneity. Sensitivity analysis was performed to assess the stability of this meta-analysis model. Fagan plots and likelihood ratio scattergrams were used to explore the potential clinical significance.
Ten eligible studies with 514 controls and 557 patients were included in this diagnostic meta-analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.75 (95% CI: 0.65-0.83), 0.84 (95% CI, 0.78-0.89), 5.87 (95% CI, 3.67-9.38), 0.28 (95% CI, 0.19-0.40), and 21.15 (95% CI, 10.25-43.68), respectively. The AUC was 0.89 (95% CI, 0.86-0.91). Sensitivity analysis showed that four studies had an impact on the pooled results and mainly contributed to the heterogeneity. Fagan's nomogram revealed that the prior probability of 20%, the post probability positive, the post probability negative were 59% and 6%, respectively.
Our results suggested that exosomal circRNAs might serve as powerful biomarkers in detecting cancers with high sensitivity and specificity. However, more well-designed and multicenter diagnostic tests are needed to validate our results.
最近,血清外泌体环状 RNA(circRNA)被用于区分癌症患者和健康个体,表明外泌体 circRNA 有可能成为癌症诊断的新型生物标志物。本研究旨在通过荟萃分析总结外泌体 circRNA 在癌症诊断中的作用。
系统检索 PubMed、Web of Science、EMBASE 和 Cochrane 数据库,截至 2021 年 7 月,以评估诊断价值,汇总灵敏度、特异度、阳性似然比(PLR)、阴性似然比(NLR)、诊断比值比(DOR)和曲线下面积(AUC)。采用亚组分析和 meta 回归分析进行阈值效应分析,以探讨异质性的来源。采用敏感性分析评估该荟萃分析模型的稳定性。采用 Fagan 图和似然比散点图探讨潜在的临床意义。
本诊断性荟萃分析纳入 10 项研究,共纳入 514 例对照和 557 例患者。汇总灵敏度、特异度、PLR、NLR 和 DOR 分别为 0.75(95%CI:0.65-0.83)、0.84(95%CI:0.78-0.89)、5.87(95%CI:3.67-9.38)、0.28(95%CI:0.19-0.40)和 21.15(95%CI:10.25-43.68),AUC 为 0.89(95%CI:0.86-0.91)。敏感性分析显示,有 4 项研究对汇总结果有影响,主要导致异质性。Fagan 列线图显示,先验概率 20%时,阳性后验概率、阴性后验概率分别为 59%和 6%。
本研究结果表明,外泌体 circRNA 可能作为一种强大的生物标志物,用于检测具有高灵敏度和特异性的癌症。然而,需要更多设计良好且多中心的诊断性试验来验证我们的结果。